New Oral Anticoagulants: An Update

Authors

  • Quamruddin Ahmad Prof. & Head, Department of Neuromedicine, Holy Family Red Crescent Medical College (HFRCMC), Dhaka
  • Md Mahin Reza Resident, Department of Neuromedicine, HFRCMC, Dhaka
  • Md Ahosan Habib Registrar, Department of Neuromedicine, HFRCMC, Dhaka
  • Syed Faravee Masud Resident, Department of Neuromedicine, HFRCMC, Dhaka
  • - Nasiruddin Resident, Department of Neuromedicine, HFRCMC, Dhaka
  • Md Ahsanuzzaman Khan Resident, Department of Neuromedicine, HFRCMC, Dhaka
  • Ahmed Shahed e Ambiya Resident, Department of Medicine, HFRCMC, Dhaka
  • Sonia Nasreen Ahmad Assistant Professor, Department of Medicine, Holy Family Red Crescent Medical College, Dhaka

DOI:

https://doi.org/10.3329/jbcps.v37i3.41736

Keywords:

Oral Anticoagulants, Rivaroxaban, Apixaban

Abstract

One of the most common and useful forms of medical intervention is anticoagulant therapy and it is the mainstay of treatment and prevention of thrombosis in different clinical settings, like atrial fibrillation (AF), acute coronary syndrome (ACS), acute venous thromboembolism (VTE), and in patients undergoing invasive cardiac procedures. More than 6 million patients in the United States receive long-term anticoagulation therapy for the prevention of thromboembolism due to AF, placement of a mechanical heart-valve prosthesis, or VTE.1 For more than 60 years, until 2009, warfarin and other vitamin K antagonists were the only class of oral anticoagulants (OAC) available. Although these drugs are highly effective in prevention of TE, their use is limited by a narrow therapeutic index that necessitates frequent monitoring and dose adjustments. This results in substantial risk and inconvenience, leading to inadequate anticoagulant prophylaxis. Recently some new OAC have been marketed which are effective, easier to use and has less side effects. Dabigatran is a new oral thrombin inhibitor and Rivaroxaban, Apixaban and Edoxaban are oral factor Xa inhibitors. This review outlines why these new OACs were essential and describes in detail about these new drugs.

J Bangladesh Coll Phys Surg 2019; 37(3): 135-150

Downloads

Download data is not yet available.
Abstract
1479
PDF
684

Downloads

Published

2019-06-12

How to Cite

Ahmad, Q., Reza, M. M., Habib, M. A., Masud, S. F., Nasiruddin, .-., Khan, M. A., Ambiya, A. S. e, & Ahmad, S. N. (2019). New Oral Anticoagulants: An Update. Journal of Bangladesh College of Physicians and Surgeons, 37(3), 135–150. https://doi.org/10.3329/jbcps.v37i3.41736

Issue

Vol. 37 No. 3 (2019)

Section

Review Articles

License

Submission of a manuscript for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted manuscripts become the permanent property of the Journal of Bangladesh College of Physicians and Surgeons and may not be reproduced by any means in whole or in part without the written consent of the publisher.

No part of the materials published in this journal may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Reprints of any article in the Journal will be available from the publisher.